Navigation Links
Mylan Receives WHO Approval for Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment
Date:12/20/2011

PITTSBURGH, Dec. 20, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:

  • Atazanavir Capsule, 300 mg, Ritonavir Tablet, 100 mg (heat-stable), and Tenofovir Disoproxil Fumarate and Lamivudine Tablet 300 mg/300 mg, or "second-line-in-a-box"
  • Fixed-dose combination Atazanavir Sulfate and Ritonavir Tablets, 300 mg/100 mg
  • Fixed-dose combination Abacavir Sulfate, Lamivudine and Zidovudine Tablets, 300 mg/150 mg/300 mg

Mylan President Heather Bresch said: "With these three approvals, Mylan will further enhance our portfolio of more convenient, more affordable treatment options for people in the developing world living with HIV/AIDS. In particular, we are proud to deliver on a previous commitment that we made through an announcement with President Bill Clinton on August 6, 2009[1], to lower the price of second-line treatments for patients with drug-resistant HIV in developing countries. Further, these product combinations and packaging solutions are an example of our continued commitment to innovation in an effort to increase treatment adherence and effectiveness. By bringing these medicines to market through WHO's Prequalified Medicines Programme, we are again delivering on our promise to expand access to critical, life-saving ARV medicines for patients who need them in the developing world."

Atazanavir Capsule, 300 mg, Ritonavir Tablet, 100 mg (heat-stable), and Tenofovir Disoproxil Fumarate and Lamivudine Tablet 300 mg/300 mg, is a co-packaged product that makes available a once-daily treatment for patients who have de
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mylan Launches Generic Version of Toprol-XL® Tablets
2. Mylan Names John Thievon President of Dey Pharma
3. Mylan Launches Generic Version of Cyklokapron® Injection
4. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
5. Mylan Launches Generic Version of Caduet® Tablets
6. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
7. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
8. Mylan Receives Approval for Generic Version of Zinecard® for Injection
9. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
10. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
11. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- goBalto, Inc., the leading provider of cloud-based clinical study ... Red Herring,s Top 100 Global award. goBalto ... in 2013, marking its emergence as a top player ... Top 100 Global list has become a mark of ... Herring editors were among the first to recognize that ...
(Date:11/26/2014)... , Nov. 25, 2014  Medtronic,s roughly ... has been widely discussed in the media for ... creating a stronger leading player in one of ... Information.  The healthcare market research firm said  the ... feature a diverse set of solutions spanning inpatient ...
(Date:11/26/2014)... Heska Corporation (NASDAQ: HSKA ) - ( ... advanced veterinary diagnostic and other specialty veterinary products , announced ... The Benchmark Company, LLC,s Micro Cap Discovery Conference on Thursday, ... The Palmer House Hilton, 17 E. Monroe Street, ... Please email hska@haydenir.com or contact your Benchmark representative ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Heska to Attend Benchmark Micro Cap Discovery Conference 2
... ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces that positive ... of ZIO-201 (isophosphoramide mustard,- IPM) to treat ... Society of Medical Oncology (ESMO) meeting held ... entitled, "Phase-I/II,Study of IPM (ZIO-201) In Advanced ...
... - TransPharma Medical,Ltd., a specialty pharmaceutical company ... products utilizing a proprietary,active transdermal drug delivery ... I clinical trials demonstrating the,safety and pharmacokinetic ... treatment of osteoporosis., A seven day, repeated ...
Cached Medicine Technology:Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... Cardiology have launched a partnership designed to improve ... for congestive heart failure (CHF) patients in the ... staff and Lourdes Cardiology team will help CHF ... supervised protocols. This partnership pairs the Cardiac Recovery ...
(Date:11/26/2014)... 2014 Increasing incidence rate of ... regulations are expected to be prime pharmacovigilance market ... of acute and chronic ailments has resulted in ... development. Moreover, growing adverse drug reaction related hospitalization ... become the need of the hour in the ...
(Date:11/26/2014)... NC (PRWEB) November 26, 2014 German ... of materials science can cause mesothelioma that looks and ... posted a new article on the research. Click ... the Fraunhofer Institute for Toxicology and Experimental Medicine in ... While all of the rats eventually developed ...
(Date:11/26/2014)... The city of San Diego, California, ... forward with a plan to recycle wastewater – also ... Kleyne supports the San Diego plan as part of ... to Kleyne, by recycling water that San Diego already ... be greatly reduced. (Spagat, E, “San Diego looks to ...
(Date:11/26/2014)... 2014 Loffler Companies has been selected ... Imaging, an online information and news publication for resellers ... sixth consecutive year Loffler has earned this prestigious award ... Elite Dealer Awards honor the best and the brightest ... Dealer honorees were chosen for their innovative marketing and ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2
... new modus operandi at Britain’s farm ministry, with a view ... in the bud, as a preparation before the autumn season. ... gulls and waders, seen as potential H5N1 disseminators of infection ... surveillance and testing in the areas frequented by migratory birds. ...
... adults are estimated to use complementary and alternative therapies ... results of a// national survey published in the September ... issue on sleep. ,Approximately 10 to 34 ... as insomnia, according to background information in the article. ...
... Thiruvananthapuram said that there was no need to panic after ... were reported in the city.// ,Health authorities said that ... to pelt the state. The chikungunya scare so far was ... be confined to some pockets as mosquitoes are increasing due ...
... mosquito-caused illness is causing panic in the city.// ,As per ... city but four patients with its symptoms are being treated. Their ... have already started a survey in the city to identify chikungunya ... medical officer D.C. Jain. ,However, there is panic in ...
... fires have forced over 1,300 people to leave their ... to battle// the hundreds of forest fires on Friday. ... worst that they have ever encountered at this time ... with smoke vulnerability like children, the elderly, the infirm ...
... study directed by Mount Sinai School of Medicine ... regimens// might halt or even reverse symptoms of ... Attenuates Alzheimer’s Disease Type Brain Amyloidosis in Squirrel ... will be published in the November 2006 issue ...
Cached Medicine News:Health News:About 5 Percent of Adults with Insomnia Use Alternative Therapies 2Health News:Chikungunya Outbreak Feared in Jaipur 2Health News:Burning fires in Northern Ontario Cause Hundreds to leave their Homes 2Health News:Calorie Restriction May Prevent, Reduce Alzheimer’s Neuropatholog 2
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... is a rapid ELISA test for Clostridium ... value and 99% sensitivity. That means the ... out C. difficile negatives - which can ... before culturing for the organism - and ...
... is a rapid immunoassay to detect Clostridium difficile ... test uses antibodies specific for toxins A and ... and >99% specificity compared to tissue culture. Because ... B, the risk of false negative results due ...
Medicine Products: